 EDINBURGH, United Kingdom, Sept. 29, 2021 GLOBE NEWSWIRE -- NuCana plc NASDAQ: NCNA announced that the U.S. Food and Drug Administration FDA has granted Fast Track designation to Acelarin NUC-1031, currently being evaluated in a Phase III study NuTide:121 for the first-line treatment of patients with advanced biliary tract cancer. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address an unmet medical need. 